LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma may also develop ensifentrine for the treatment of cystic fibrosis and asthma.
For further information, please contact:
|Verona Pharma plc||Tel: +44 (0)20 3283 4200|
|Jan-Anders Karlsson, Chief Executive Officerfirstname.lastname@example.org|
|Victoria Stewart, Director of Communications|
|N+1 Singer |
(Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate
Finance) Brough Ransom /Mia Gardner (Corporate Broking)
|Tel: +44 (0)20 3283 4200|
|Optimum Strategic Communications |
(European Media and Investor enquiries)
|Tel: +44 (0) 203 922 0891 |
|Mary Clark, Anne Marieke Ezendam, Hollie Vile|